Items tagged with Vaccines
Gates MRI looks to Phase 3 TB vaccine trial with epidemiology study (post)
The Bill & Melinda Gates Medical Research Institute (MRI) is conducting a TB epidemiology study: setting the stage for a Phase 3 efficacy trial for its investigational TB vaccine.
It would take 500 years for TB vaccine development to get as much money as COVID-19 (post)
In the two years since covid-19 put the world on pause, the progress the scientific community has made against the disease has been astounding. New vaccines, using new technology, have been developed in record time, and are already in the arms of billions around the world.
IAVI and Moderna partner to tackle broad global health priorities using mRNA for vaccines and antibodies (post)
NEW YORK, NY and CAMBRIDGE, MA / April 7, 2022 / Moderna, Inc., (NASDAQ:MRNA) a biotechnology company pioneering messenger RNA (mRNA) therapeutics and vaccines, and the nonprofit scientific research organization IAVI today announced a new collaboration to employ mRNA technology to meet the challenge of a range of global health threats. These diseases - HIV/AIDS, tuberculosis (TB), antimicrobial-resistant enteric infections, and COVID-19 - are estimated to have caused at least 95 million new infections and more than 4 million deaths in 2020 alone. The collaboration combines the power of Moderna's mRNA platform and IAVI's expertise in discovery and product development to advance vaccines and antibodies designed to be globally accessible, especially in low-income countries where the targeted diseases have high incidence and prevalence.
The new frontier: Spotlight series on mRNA vaccine technology (post)
Messenger ribonucleic acid — known as mRNA — was discovered in the 1960s, but it has reached new heights of popularity among vaccine developers due to its flexibility and adaptability to emerging infectious diseases.
Can we improve on a once-in-a-century TB vaccine? (post)
CAIRNS, April 26 – Tuberculosis (TB) remains one of the deadliest infectious diseases known to humankind. The existing TB vaccine is highly protective, but it has some limitations.
Evaluation of the potential of new and repurposed TB vaccines (post)
Scientists reported that tuberculosis (TB) is one the foremost causes of global mortality, especially in adults. In 2019, around 10 million TB cases were reported, many of which were identified to be resistant to multiple drugs.
Why is the 100-year-old BCG vaccine so broadly protective in newborns? (post)
The century-old Bacille Calmette-Guérin (BCG) vaccine against tuberculosis is one of the world’s oldest and most widely used vaccines, used to immunize 100 million newborns every year. Given in countries with endemic TB, it has surprisingly been found to protect newborns and young infants against multiple bacterial and viral infections unrelated to TB. There’s even some evidence that it can reduce severity of COVID-19.
This vaccine could save tens of thousands of South African lives each year, but we’ll only see it in 2030 (post)
In 2019, the World Health Organisation (WHO) hailed the results of a candidate tuberculosis (TB) vaccine as a major scientific breakthrough. But years later we are not much closer to seeing the vaccine. Why do TB vaccines take so long to develop compared to Covid vaccines?
ICMR to begin study to evaluate BCG booster dose for kids, adolescents (post)
This study will demonstrate the effect of BCG revaccination in comparison to oral chemoprophylaxis on the incidence of mycobacterium tuberculosis disease in healthy household contacts, aged 6-18 years.
Aerosol-based TB vaccine begins human trials (post)
6 July 2022: The University of Oxford has begun recruiting for a Phase I trial with a tuberculosis vaccine in human volunteers at Oxford to develop a new way to test the efficacy of future TB vaccines – with the first volunteers being challenged today (Wednesday).
Page 20 of 32 · Total posts: 0
←First 19 20 21 Last→